Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

Gureje, O, Miles, W, Keks, N, Grainger, D, Lambert, T, McGrath, J, Tran, P, Catts, S, Fraser, A, Hustig, H, Andersen, S and Crawford, AM (2003) Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophrenia Research, 61 2-3: 303-314. doi:10.1016/S0920-9964(02)00226-8


Author Gureje, O
Miles, W
Keks, N
Grainger, D
Lambert, T
McGrath, J
Tran, P
Catts, S
Fraser, A
Hustig, H
Andersen, S
Crawford, AM
Title Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand
Journal name Schizophrenia Research   Check publisher's open access policy
ISSN 0920-9964
Publication date 2003-01-01
Sub-type Article (original research)
DOI 10.1016/S0920-9964(02)00226-8
Volume 61
Issue 2-3
Start page 303
End page 314
Total pages 12
Place of publication Amsterdam
Publisher Elsevier Science Bv
Language eng
Abstract Improved drug therapy for schizophrenia may represent the best strategy for reducing the costs of schizophrenia and the recurrent chronic course of the disease. Olanzapine and risperidone are atypical antipsychotic agents developed to meet this need. We report a multicenter, double-blind, parallel, 30-week study designed to compare the efficacy, safety, and associated resource use for olanzapine and risperidone in Australia and New Zealand. The study sample consisted of 65 patients who met DSM-IV criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder. Olanzapine-treated patients showed a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores at endpoint compared to the risperidone-treated patients. Response rates through 30 weeks showed a significantly greater proportion of olanzapine-treated patients had achieved a 20% or greater improvement in their PANSS total score compared to risperidone-treated patients. Olanzapine and risperidone were equivalent in their improvement of PANSS positive and negative scores and Clinical Global Impression-Severity of Illness scale (CGI-S) at endpoint. Using generic and disease-specific measures of quality of life, olanzapine-treated patients showed significant within-group improvement in most measures, and significant differences were observed in favor of olanzapine over risperidone in Quality of Life Scale (QLS) Intrapsychic Foundation and Medical Outcomes Study Short Form 36-item instrument (SF-36) Role Functioning Limitations-Emotional subscale scores. Despite the relatively small sample size, our study suggests that olanzapine has a superior risk:benefit profile compared to risperidone. (C) 2002 Elsevier Science B.V. All rights reserved.
Keyword Psychiatry
Olanzapine
Risperidone
Schizophrenia
Quality Of Life
Haloperidol
Scale
Reliability
Clozapine
Disorders
Placebo
Drugs
Panss
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 66 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 71 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 13 Aug 2007, 23:33:54 EST